Michael Charlton MD, FRCP

Director of University of Chicago Transplant Institute. #livertwitter #cirrhosis #liverdisease #NASH #Life. Tweets are my own.

[Michael Charlton MD, FRCP @mcharltonmd]

The ILC at EASL winds down. Best ever. This was our Last Supper.

[Michael Charlton MD, FRCP @mcharltonmd]

New fave pic. On the L is Stefano Romeo, 1st author on PNPLA3 in MASLD Nature paper. On the R is Greg Tesz, lead scientist at Pfizer for first PNPLA3 Rx in human studies. From genetic assn to clinical trial. I ❤️ it! Keystone Symposia are a lot of work. But worth it! 💪 2gether.

[Michael Charlton MD, FRCP @mcharltonmd]

Some early Keystone insights: Weight loss is less of a driver of MASLD histology than we thought. FFA are the major source of hepatic lipids (not DNL) and we are what our parents ate, at least epigenetically. 🤔

[Michael Charlton MD, FRCP @mcharltonmd]

Keystone MASH and Fibrosis: Molecular Phenotypes to Precision Therapeutics has kicked off with Arun Sanyal delivering the Keynote opener. A masterful synthesis of a doyen’s knowledge!

[Michael Charlton MD, FRCP @mcharltonmd]

@TCotterMD @NIAAAnews @docamitgs @ebtapper @DrLiver @KatieWitkiewitz @UTSWGI @SoniaKupfer @anouti_ahmad Congratulations Thomas! This is a new peak of what has been an amazing journey. Your commitment and original thinking have brought you a long and deserved way! It has been a joy to watch you grow from fellow to PI!

[George Ioannou @gnioannou]

In this meta-analysis of individual patient data, liver biopsy performed the same as FIB-4, fibroscan liver stiffness and NAFLD fibrosis score in predicting clinical outcomes up to 10 yrs in pts with NAFLD

Time to abandon liver biopsies!
➡ Use FIB-4!

https://t.co/4dvCN17IjV

[Jeffrey V. Lazarus @JVLazarus]

@ebtapper The #MASLDnomenclature article in @HEP_Journal https://t.co/0sv7sOVz2z is now ranked 16th of >8500 articles tracked by @altmetric in Hepatology and is in the top 50k all time:
https://t.co/r8yNDZag37
Keep sharing and expand the community of practice:
https://t.co/M2vlRrbhU6

[Michael Charlton MD, FRCP @mcharltonmd]

@AlinaAllenMD @marurinella @SagiZelber @schattenbergJ @JVLazarus @HenryEMark @AlkhouriNaim @NoureddinMD @DrMTLong @SonalKumarMD @WRayKimMD @AleksanderKrag @AlinaAllenMD no doubt you are right. I also think the pandemic has accelerated changes in how medical professionals perceive scientific conferences and how we use digital information.
Networking (and viewing a Klimt in person to violin accompaniment!) will require travel!

[Michael Charlton MD, FRCP @mcharltonmd]

Some thoughts on the first in person EASL / ILC meeting since pandemic:
👉Attendance for major meetings (AASLD, EASL) ~60% of peak pre-COVID. Will be $$ challenges.
👉In person far superior to Zoom etc.
👉Liver science is accelerating (NASH, HCC and HBV on 🔥)
👉🙏🏻👏 #EASL

[Michael Charlton MD, FRCP @mcharltonmd]

@FattyLiverA @FrancqueSven Hard to beat Viennese opera!
Did NAFLD and MAFLD sing in closing act?

[BBC Morning Live @BBCMorningLive]

Over 10,000 lives are lost to liver disease in the UK each year. On Monday’s show, Dr @xandvt joins us to talk about the condition and the lifestyle changes we can make to reduce our risk of getting the disease.

📧 Do you have a question for Dr Xand? Get in touch now.

[Oren Fix @orenkfix]

When is the last time this many organizations agreed on something? This is an impressive turnout in support of the new nomenclature to replace NAFLD/NASH. Start using MASLD and MASH!

#LiverTwitter @aasldtweets #MASLDNomenclature @alehlatam @EASLnews

[Michael Charlton MD, FRCP @mcharltonmd]

MASLD-tov!! #livertwitter ⁦@AASLDtweets⁩ ⁦@EASLnews⁩ ⁦@alehlatam⁩ ⁦@NoureddinMD⁩ ⁦@AlkhouriNaim⁩ ⁦@JVLazarus⁩ ⁦@ebtapper⁩ ⁦@juanpabloarab⁩ ⁦@rabataller⁩ @phil_newsome7

[Michael Charlton MD, FRCP @mcharltonmd]

@UChicagoGI @AASLD @EASL fewer bigger moments in hepatology than bringing together over 60 medical societies to redefine the most prevalent liver disease in an inclusive way that removes stigma. Proud to have UChicago’s Maru Rinella leading the effort!! https://t.co/UYuPUqPt0x

[AASLD @AASLDtweets]

It’s true! #NAFLDNomenclature is now known as #MASLDNomenclature. MASLD (pronunciation: Ma-zuld) encompasses patients who have hepatic steatosis w/at least 1 (out of 5) cardiometabolic risk factors. Read the joint publication at https://t.co/9ayzwMI77T #LiverTwitter

[Michael Charlton MD, FRCP @mcharltonmd]

The guard has changed. Thank you and farewell NAFLD, NASH and MAFLD. Welcome SLD, MASLD and MASH! Well done and thank you to the Delphi panel and the 60+ medical societies who have already endorsed. @AASLDtweets @EASLnews @marurinella @phil_newsome7 @GlobalLiver @LiverSaver

[Michael Charlton MD, FRCP @mcharltonmd]

With OCA a new casualty of a palpably capricious FDA review process, not only is an effective agent lost and the field chilled but the costs of unscientific adcom decisions will be baked into Rx costs. FDA review shouldn’t resemble a ride in the Titan sub. #LiverTwitter #FDA

[Michael Charlton MD, FRCP @mcharltonmd]

@UCSD_GI @DrLoomba Congratulations Rohit, and UCSD! An inspired choice!

[Michael Charlton MD, FRCP @mcharltonmd]

Mine too!

[Meena Bansal @MeenaBBansal]

My favorite family @ddw2023 ⁦@AASLDtweets⁩ #livertwitter ⁦@DrLoomba⁩ ⁦@NoureddinMD⁩ ⁦@marurinella⁩ ⁦⁦@mcharltonmd⁩ ⁦@DOMSinaiNYC⁩

[Michael Charlton MD, FRCP @mcharltonmd]

Important topic + great investigators and speakers = Think differently by the conclusion of the conference. See you there!! Banff quite a nice place too.

[Stefano Romeo @stefano_romeo76]

Interested in NASH and precision therapeutics? I look forward to seeing you all at the 2024 Keystone on NASH and fibrosis in Banff!